Is Aristo Bio-Tech overvalued or undervalued?
As of September 17, 2025, Aristo Bio-Tech is considered expensive and overvalued with a PE Ratio of 23.31, despite outperforming the Sensex with a 30.95% return, as it trades at a premium compared to its earnings growth potential and is more expensive than some peers like Sharda Cropchem.
As of 17 September 2025, the valuation grade for Aristo Bio-Tech has moved from very expensive to expensive. The company is currently considered overvalued based on its financial ratios and peer comparisons. Key ratios include a PE Ratio of 23.31, an EV to EBITDA of 12.45, and a PEG Ratio of 5.68, which suggest that the stock is trading at a premium compared to its earnings growth potential.In comparison to its peers, Aristo Bio-Tech's PE Ratio of 23.31 is significantly lower than UPL's 39.58, indicating that while Aristo is expensive, it is not as overvalued as some of its competitors. However, it is still higher than Sharda Cropchem's PE of 19.35, which is considered attractive. Notably, Aristo Bio-Tech's recent stock performance has outpaced the Sensex, with a 1-year return of 30.95% compared to a decline of 0.35% in the Sensex, reinforcing the notion of its overvaluation amidst a strong market performance.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
